Huabang Health Establishes Joint Venture for Innovative Drug R&D Platform

# HUAPONT LIFE SCIENCES and Shenzhen Pregene Biopharma to Establish Joint Venture for Drug R&DMarch 19 (Yiou Health) – HUAPONT LIFE SCIENCES announced that it has signed an agreement with Shenzhen Pregene Biopharma Co., Ltd. (“Pregene Biopharma”) to jointly establish Shenzhen Huapu Pharmaceutical R&D Co., Ltd. (“Huapu Company”). Under the agreement, HUAPONT LIFE SCIENCES will contribute RMB 16.5 million in registered capital, holding a 55% equity stake, while Pregene Biopharma will contribute RMB 13.5 million, holding a 45% equity stake.

It is reported that Huapont, as a high-tech biotechnology R&D platform, will initially conduct research on immunological disease projects in dermatology, respiratory medicine, ophthalmology, and anti-infection, and expand to other areas with broad clinical medical demands at the appropriate time.Innovative DrugsProjects. Currently, Huapu Company’s candidate projects for early-stage target/product selection include: psoriasis (IL-17/IL-23), ankylosing spondylitis (IL-17), rheumatoid arthritis (IL-17/TNF-α/IL-6), allergic asthma (IgE/IgE antagonist) (IL-5), systemic lupus erythematosus (SLE) (IL-6), adult acquired thrombotic thrombocytopenic purpura (aTTP), and atopic dermatitis.

As disclosed in the announcement,Pregene, the partner in this agreement, was established in 2015 and its main business isCAR-T CellsDrug and Nanobody Drug Development.In the development of CAR-T cell therapies, candidates indicated for acute lymphoblastic leukemia and multiple myeloma have successively entered the Investigational New Drug (IND) application phase. In the realm of nanobody therapeutics, Pregene has established a comprehensive nanobody drug discovery platform and jointly founded a Nanobody Therapeutics Laboratory with the Chinese Academy of Sciences. Its EGFR-targeted nanobody CAR-T therapy for solid tumors is currently undergoing non-registration clinical trials in China. Furthermore, its VEGF-targeted nanobody is being co-developed as a radiopharmaceutical in collaboration with the U.S.-based BAMF Health VEGF Limited Liability Company.

China’s innovative drug market is booming. As insurance coverage and individual spending power continue to rise, hospital medication is at a turning point of structural adjustment under policy guidance, and products with clear clinical efficacy will enjoy substantial market potential.Furthermore, Chinese generic drugs are gradually expanding into overseas markets, while the broader field of innovative patented drugs remains a blue ocean. This sector is poised to become a key strategic direction for the future development of China’s pharmaceutical enterprises.

HUAPONT LIFE SCIENCES, formerly known as Huapont Pharmaceutical, was established in 1992.Its main business activities include the research and development, production, and sales of pharmaceuticals and agrochemical products, as well as medical services and tourism investment, with pharmaceutical manufacturing serving as its core business.It is understood that in 2018, the company concentrated its resources on advancing the consistency evaluation of its marketed products, while leveraging API exports to explore opportunities in the international formulation market.

The announcement further disclosed that, following the establishment of Huapu Company, HUAPONT LIFE SCIENCES will engage Shenzhen Pregene Biopharma Co., Ltd. to conduct research and development of novel antibody drugs, thereby providing innovative biopharmaceutical products with market potential through Huapu Company to pharmaceutical enterprises within its system. Furthermore, HUAPONT LIFE SCIENCES will leverage Pregene’s advantages in nanobody technology to strategically position promising products in the field of novel biologics ahead of time, thereby capturing market share.

The establishment of Huapont Company has, to some extent, aligned with the current national efforts to deepen reforms in the pharmaceutical industry and vigorously support innovation.New Drug Developmentpolicy orientation. This collaboration can supplement HUAPONT LIFE SCIENCES' existing businesses, such as dermatology and respiratory tuberculosis, with nanobody drug products that have clinical value and market advantages, providing support for the continuous development of HUAPONT LIFE SCIENCES.

With the release of the “Outline of the ‘Healthy China 2030’ Planning Program” and the deepening of healthcare reform policies, China’s medical service industry is entering a new phase of upgrading, characterized by a shift from “scale” to “value.” As the medical industry increasingly integrates with new technologies, purely volume-driven medical services are no longer the preferred investment choice, and numerous “pseudo-demands” will be eliminated as consumers “vote with their feet.” How can one navigate this crisis, leverage emerging opportunities, and ultimately stand out in 2019 in the aftermath of the capital winter?

July 25–27, 2019: Yiou Big Health to Host“GIIS 2019: The 4th China Health Industry Upgrade Summit”The summit, themed “Yanqi Health Talk: Healthcare Transformation from [Scale] to [Value],” focused on discussions around market environments, investment hotspots, and industrial transformations in four key sectors: healthcare big data, pharmaceutical innovation, private healthcare, and health technology. Meanwhile, EO Healthcare will hold a series of events from March to April:Pharmaceutical Innovation Industry Salon (March 22)、Medical Big Data Industry Salon (March 29)、Non-Public Healthcare Industry Salon (April 26)、Tech-Medical Industry Salon (April 19)Welcome to follow us!

Event Registration Link:https://www.iyiou.com/post/ad/id/785

Copyright Statement

Source: YiOu. Published with authorization from YiOu. All rights reserved by the original author. For reprinting or content collaboration, please refer to the reprint guidelines. Unauthorized reprinting will be subject to legal action.